Get research updatesPublic study records, presented in a clearer and more patient-friendly format for mental health research discovery.
This study evaluates the safety and effectiveness of SPD465 for people with ADHD.
This study was withdrawn before enrollment.
In Tampa
A Study of SPG Block for Opioid Withdrawal
This study has finished and is no longer accepting participants.
In New York
Computational Analysis of Spoken Language in Mania
This study has finished and is no longer accepting participants.
In RochesterA Study of Strategies to Improve Schizophrenia Treatment
Read the official source — NCT00156637A Study of Strategies to Improve Schizophrenia Treatment
This study has finished and is no longer accepting participants.
Multiple locations, including FayettevilleA 24-Week, Flexible-Dose, Open-label Extension Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder (Protocol No. D1050290)
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockResearchers compared Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride and placebo, tracking side effects to assess safety in children and adolescents with ADHD.
This study has finished and is no longer accepting participants.
Multiple locations, including DothanA Study of Taurine in Patients With First-episode Psychosis Receiving Antipsychotic Treatment
Read the official source — NCT00420823A 12-week, Parallel, Double-blind, Randomised, Placebo-controlled Adjunctive Study of Taurine 4 Grams in 128 Patients With First-episode Psychosis Receiving Antipsychotic Treatment.
This study has finished and is no longer accepting participants.
In MelbourneA Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
This study has finished and is no longer accepting participants.
Multiple locations, including BradentonAssociation Between Tobacco Smoking and Bipolar Affective Disorder.Clinico-epidemiological, Cross-sectional, Retrospective Study.
This study has finished and is no longer accepting participants.
In Tirat HaCarmelA Single-dose, Open-label, Randomized, 2-way Crossover Pivotal Bioequivalence Study of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and Vacaville Under Fasted Condition in Healthy Subjects
This study has finished and is no longer accepting participants.
Location not clearly listedA Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder
Read the official source — NCT00206102A Multicenter, Open Label, Flexible-dose, Parallel-group Evaluation of the Cataractogenic Potential of Quetiapine Fumarate (Seroquel) and Risperidone (Risperdal) in the Long Term Treatment of Participants With Schizophrenia or Schizoaffective Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockEvaluation of the Dose Proportionality of Two Dose Strengths (1.5 and 3 mg) of Extended-release Paliperidone After a Single Administration to Healthy Men
This study has finished and is no longer accepting participants.
Location not clearly listedWe gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.